Crossmark

Targeting myeloid differentiation protein 2 ameliorates rheumatoid arthritis by inhibiting inflammation and ferroptosis via MAPK and NF-κB signaling pathways

Crossref DOI link: https://doi.org/10.1007/s00109-025-02555-8

Published Online: 2025-05-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Lirun

Yang, Tong

Zhang, Shujie

Liu, Dandan

Feng, Chenran

Ni, Jiang

Shi, Qiaoli

Liu, Yanqing

Meng, Yuqing

Zhu, Yongping

Tang, Huan

Wang, Jigang

Ma, Ang https://orcid.org/0009-0002-9988-8670
Funding

Funding for this research was provided by:

National Natural Science Foundation of China under grants (81800388)

Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences (2022-JKCS-15)
License Information

Text and Data Mining valid from 2025-05-21

Version of Record valid from 2025-05-21
More Information

Article History

Received: 4 April 2025

Revised: 8 May 2025

Accepted: 12 May 2025

First Online: 21 May 2025

Declarations

:

: All procedures adhered to the Declaration of Helsinki and were approved by the Medical Ethics Committee of the Affiliated Hospital of Jiangnan Science (Ethical approval number: LS2024080).Animal experimental protocols were approved by the Ethics Committee of China Academy of Chinese Medical Sciences (2023B298).

: The authors declare no conflicts of interest to disclose.

Document is current

Any future updates will be listed below